title: Effect of oral cephalexin in the treatment of BCG lymphadenitis.
abstract: Lymphadenitis and abscess formation are the most common side effects of vaccination with Bacille Calmette Guerin (BCG). The lower the child's age at the time of vaccination, the higher the incidence of BCG lymphadenitis tends to be. Although various therapeutic approaches are in use for the treatment of BCG lymphadenitis, there is no consensus on which of them is optimal. This study aimed to determine whether oral cephalexin treatment hastens recovery from BCG lymphadenitis. The study involved 40 children (24 boys and 16 girls) with BCG lymphadenitis who were referred to Qazvin Children's Hospital, Qazvin University of Medical Sciences between December 2008 and the end of September 2009. The patients were randomly assigned to two groups of 20 patients each (12 boys and 8 girls in each group): group A patients did not receive any treatment and served as controls, and group B patients were treated with 50 mg/kg/day cephalexin syrup, administered in four doses, for 10 days. In all patients, clinical examination was normal, except for lymphadenitis. In all patients, BCG vaccination had been performed at birth, and polymerase chain reaction tests were positive for tuberculous bacilli. The recovery period and requirement of fine needle aspiration did not significantly differ between the two groups (P 0.05). This study showed that treatment with cephalexin does not hasten recovery from BCG lymphadenitis.
authors: Department of Paediatric Infectious Diseases; Department of Paediatrics; Metabolic Diseases Research Center, Qazvin University of Medical Sciences, Qazvin, Iran.
authors: Parviz
authors: P
authors: Ayazi
authors: Department of Paediatric Infectious Diseases; Department of Paediatrics; Metabolic Diseases Research Center, Qazvin University of Medical Sciences, Qazvin, Iran.
authors: Abolfazl
authors: A
authors: Mahyar
authors: Department of Paediatric Infectious Diseases; Department of Paediatrics; Metabolic Diseases Research Center, Qazvin University of Medical Sciences, Qazvin, Iran.
authors: Alireza
authors: A
authors: Taremiha
authors: Department of Paediatric Infectious Diseases; Department of Paediatrics; Metabolic Diseases Research Center, Qazvin University of Medical Sciences, Qazvin, Iran.
authors: Najmeh
authors: N
authors: Ghorani
authors: Department of Paediatric Infectious Diseases; Department of Paediatrics; Metabolic Diseases Research Center, Qazvin University of Medical Sciences, Qazvin, Iran.
authors: Neda
authors: N
authors: Esmailzadehha
mesh_terms: D000276:Adjuvants, Immunologic / Q000009:adverse effects*; D000284:Administration, Oral; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D001500:BCG Vaccine / Q000009:adverse effects*; D044963:Biopsy, Fine-Needle; D016022:Case-Control Studies; D002506:Cephalexin / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007223:Infant; D007492:Iran; D008199:Lymphadenitis / Q000175:diagnosis / Q000209:etiology* / Q000628:therapy*; D008297:Male; D016896:Treatment Outcome
chemical_list: D000276:Adjuvants, Immunologic; D000900:Anti-Bacterial Agents; D001500:BCG Vaccine; D002506:Cephalexin